What is the New Biology ?

The publication of the first human genome sequence in 2001 marked the beginning of a period of explosive growth and proliferation in biology. Since then, entire new sciences have been born and radically new techniques have been developed. Biological data can now be generated so rapidly that it resembles water from a fire hose.

Medical applications have mushroomed. Developments include DNA and RNA based diagnostics, new classes of therapeutics, and inventive new devices and procedures. "Personalized medicine" is now a familiar term, which points us to a world in which medicine is custom-tailored to each individual's personal genetic makeup.

Together, these developments make up the "New Biology" -- an emerging science driven by ever deeper understandings of the molecular basis of life. The New Biology is here to stay. It holds tremendous promise and continues to expand into new arenas.

The role of New Biology Resources

Commercial implications of the New Biology are enormous. For companies in this sector, an essential need is effective communications with the sophisticated and highly specialized scientists and physicians who drive technical advances and then move them into the real world.

These people are the lifeblood of any NewBio company. They are suppliers, advisors, colleagues, and in many cases, customers as well. NewBioRes facilitates productive interactions between companies and the M.D. and Ph.D. level physicians and scientists they work with. This includes communcations in both directions, outward and inward.

About Dr. Whipple

Dr. Fred Whipple is a molecular biologist with extensive at-the-bench research experience, incuding publications and competitive grant funding, at Harvard Medical School and Tufts Medical School. He also has academic research and teaching experience at California State University.

Since 2008 Dr. Whipple has been an independent consultant and expert sales representative for biotechnology companies. His particular areas of expertise are: DNA manipulation and sequencing; next-generation diagnostics development (including protein-based and nucleic acid-based high-throughput systems), and molecular pathology (including image-based methods, immunohistochemistry, CGH, qPCR, and flow cytometry).